Logo
About
Blog
OTCIQ
Loading...
   Stock Screener
OTC Markets
Totals
Securities
12,255
Dollar Vol
$2.6B
Share Vol
3.2B
Trades
383,044

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

CLRB
Cellectar Biosciences, Inc.

Common Stock

4.73

0.02

0.42%

Delayed (15 Min) Trade Data: 12:00am 08/08/2025
News
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025GlobeNewswire | 08/07/2025
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment OptionGlobeNewswire | 07/02/2025
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public OfferingGlobeNewswire | 07/01/2025
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply AgreementGlobeNewswire | 06/26/2025
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)GlobeNewswire | 06/24/2025
Cellectar Biosciences Announces One-for-Thirty Reverse Stock SplitGlobeNewswire | 06/18/2025
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade GliomaGlobeNewswire | 06/11/2025
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq RulesGlobeNewswire | 06/05/2025
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)GlobeNewswire | 06/04/2025
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateGlobeNewswire | 05/13/2025
More
Displaying 10 of 10 News Listings
OTC Disclosure & News Service
Filter
August 2025
Su
Mo
Tu
We
Th
Fr
Sa
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
6
August 2025
Su
Mo
Tu
We
Th
Fr
Sa
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
6
Filter
August 2025
Su
Mo
Tu
We
Th
Fr
Sa
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
6
August 2025
Su
Mo
Tu
We
Th
Fr
Sa
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
6
Cellectar Biosciences Announces Pricing of $12,500,000 Public Offering and Listing on The Nasdaq Capital MarketGlobeNewswire | 08/14/2014
Cellectar Biosciences Files Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple MyelomaGlobeNewswire | 08/11/2014
Cellectar Biosciences Announces 1-for-20 Reverse Stock Split and Reduction in Authorized Shares of Common StockGlobeNewswire | 06/13/2014
Cellectar Biosciences Announces Presentations at 2014 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire | 05/30/2014
Cellectar Biosciences Appoints Chad J. Kolean Chief Financial OfficerGlobeNewswire | 05/29/2014
Cellectar Biosciences Reports First Quarter 2014 Financial Results and Recent HighlightsGlobeNewswire | 05/14/2014
Cellectar Biosciences to Host Conference Call on May 14th to Discuss First Quarter 2014 Results and Provide Quarterly Update on Development ProgressGlobeNewswire | 05/12/2014
Cellectar Biosciences Announces Receipt of Orphan Designation of I-124-CLR1404 as Diagnostic for the Management of Glioma from U.S. Food and Drug AdministrationGlobeNewswire | 05/05/2014
Dr. Simon Pedder Becomes President and Chief Executive Officer of Cellectar BiosciencesGlobeNewswire | 04/02/2014
Cellectar Biosciences Full-Year 2013 Financial Results and Recent HighlightsGlobeNewswire | 03/25/2014
More
Displaying 10 of 24 Press Releases
Nasdaq
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.
Loading...
Symbol
OTCM
Last
55.00
Change
0.01 (0.02%)
Bid
55.00
Ask
55.10
Volume
9436
Time
00:00
Contact
Careers
Market Hours
Glossary

© 2025 OTC Markets Group Inc.

Terms of ServiceLinking TermsTrademarksPrivacy StatementCode of ConductRisk WarningSupported BrowsersLimit the Use, Disclosure or Sale of My Personal Information